Clinical Remission in Severe T2‐High Asthma in Real Life After Anti‐IgE, Anti‐IL‐5 and Anti‐IL5R: A Potential Role for CRP as a Biomarker

Puntos clave

• To evaluate the impact of biological treatments on clinical remission in severe T2-high asthma and assess the role of CRP as a biomarker.
• Analyzed clinical outcomes of severe T2-high asthmatics after anti-IgE, anti-IL-5, and anti-IL5R treatments.
• Monitored CRP levels as a potential predictive biomarker for remission.
• Measured remission rates over 12 months.
• Approximately one third of patients achieved clinical remission after treatment at 12 months.
• A low baseline CRP level may indicate a higher likelihood of achieving remission.